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Purpose or Objective: The aim of this work is to evaluate the perturbed DVHs generated from Tomotherapy dose distributions according to the dose discrepancies detected with pre-treatment measurements. Through perturbed DVHs data, sensitivity and specificity of gamma passing rate (%GP) were calculated to evaluate if Gamma Index (GI) metric correctly differentiates the high dose error plans from low dose error plans. In the literature GI was found to be a poor predictor of dosimetric accuracy with planar and volumetric dosimeters for IMRT and VMAT techniques, we evaluate if this lack of prediction of GI method is valid also for Tomotherapy plans.
Material and Methods:
12 patients for prostate cancer (P), and 12 for head and neck (HN) cancer, were enrolled in the study. All the treatments were delivered using the Helical Tomotherapy Hi-ART system (Accuray, Inc., Sunnyvale, CA). Pre-treatment QA measurements were performed by using the diode array ArcCHECKTM and perturbed DVHs were obtained with the 3DVH software (both by Sun Nuclear Corporation, Melbourne, FL). Measured and calculated dose distributions were compared using the global and local GI method with 2%/2 mm, and 3%/3 mm criteria. Low-dose thresholds (TH) of 10% and 30% were applied and analyzed. Percentage dose differences between DVHs, obtained by TPS and by 3DVH were calculated. A %GP equal to 95% and a mean absolute DVH 3% dose error were used as thresholds to calculate sensitivity and specificity. In order to quantify the sensitivity and specificity of GI method, we calculated the number of false negative (high Tomotherapy QA passing rates indicate large errors in anatomy dose metrics), true positive (low Tomotherapy QA passing rates do imply large errors in anatomy dose metrics), true negative (high Tomotherapy QA passing rates did imply small errors in anatomy dose metrics) and false positive (low Tomotherapy QA passing rates did imply small errors in anatomy dose metrics).
Results:
We found the higher sensitivity (0.55) for global normalization with 3%/3mm and TH= 30% and the higher specificity (0.67) with 3%/3mm for global normalization, both for TH 10% and 30%. Instead we obtained the poorer sensitivity (0) with 2%/2mm, local normalization, and TH=10% because the threshold of 95% is too high for 2%/2mm and local normalization. We observed the poorer specificity (0.39) for 3%/3mm, local normalization, both for TH=10% and 30%. For global normalization, 3%/3mm sensitivity and specificity were always higher than those of 2%/2mm criterion.
Conclusion:
The low sensitivity and specificity values of GI method, for all the applied criteria, show that the gamma index metric have disputable predictive power for perpatient Tomotherapy QA. 
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Purpose or Objective:
The gamma index (γ) is a common method for comparing measured and predicted dose distributions. The percentage of points passing with γ<1 (Γ) is the most frequently reported analysis metric. However, the use of Γ has been reported to have weak correlation against clinically relevant metrics and the result also varies depending on the Quality Assurance (QA) system configuration and software used. Other metrics could be extracted from the γ map but have not been rigorously evaluated in the literature to address appropriate acceptance values. This study has developed a methodology to evaluate the suitability of the mean, median, maximum, or nearmaximum γ metrics (γmean, γmedian, γmax, γ1%) and their acceptance criteria.
Material and Methods:
Investigations were performed using simulated data with deliberate changes created in a virtual phantom test. The changes included: dose deviations of -5% to 5% in 1% steps; and MLC offsets of 1-5mm in 1mm steps. An in-house Matlab-based software was used to perform γ analysis to extract different metrics. The primary PTV mean (PTVmean) and organ at risk maximum (OARmax) dose deviations were extracted from the changed plans. The γ metrics were correlated against PTVmean and OARmax for global γ passing criteria of 3%/2mm (20% threshold relative to a point in high dose low gradient). Acceptance criteria needed to predict a dose deviation >±3%, for 3%/2mm, were assessed using Receiver Operator Characteristic (ROC) analysis and assuming 100% sensitivity. The area under the ROC curve (AUC) was assessed for each γ metric to assess statistical reliability. Since the γ calculation can give varying results between different QA systems, the robustness of the proposed methodology was tested by varying γ passing criteria as well calculating in 2D planes and 3D volumes.
Results:
The γmean, γmedian and γ1% metrics had the strongest Pearson correlation coefficient (ρ) against the PTVmean (ρ>0.95, p<0.01); (Fig. 1) . The Γ had a weaker correlation of ρ=-0.76. These metrics had ROC AUC>0.9 (p<0.01) showing statistically strong accuracy for predicting a PTVmean deviation >±3% for 3%/2mm. Optimal acceptance criteria for achieving 100% sensitivity are shown in Table 1 . The γmax had the best correlation against OARmax (ρ> 0.8, p<0.01) and the AUC was >0.9 and showed that points with γ>1.1 may be associated with a >3% increase in the OARmax. Correlations between different γ passing criteria were statistically strong at >0.95 (p<0.01) as were correlations between 2D & 3D γ calculations, indicating the robustness of the methodology to the variability in γ calculation that could be caused by QA system configuration and software implementation.
